Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society.


Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
01 2023
Historique:
pubmed: 2 11 2022
medline: 1 2 2023
entrez: 1 11 2022
Statut: ppublish

Résumé

The objective of this study was to develop evidence-based recommendations on pregnancy management for persons with multiple sclerosis (MS). MS typically affects young women in their childbearing years. Increasing evidence is available to inform questions raised by MS patients and health professionals about pregnancy issues. The French Group for Recommendations in Multiple Sclerosis (France4MS) reviewed PubMed and university databases (January 1975 through June 2021). The RAND/UCLA appropriateness method was developed to synthesise the scientific literature and expert opinions on healthcare topics; it was used to reach a formal agreement. Fifty-six MS experts worked on the full-text review and initial wording of recommendations. A group of 62 multidisciplinary healthcare specialists validated the final proposal of summarised evidence. A strong agreement was reached for all 104 proposed recommendations. They cover diverse topics, such as pregnancy planning, follow-up during pregnancy and postpartum, delivery routes, locoregional analgesia or anaesthesia, prevention of postpartum relapses, breastfeeding, vaccinations, reproductive assistance, management of relapses and disease-modifying treatments. The 2022 recommendations of the French MS society should be helpful to harmonise counselling and treatment practice for pregnancy in persons with MS, allowing for better and individualised choices.

Sections du résumé

OBJECTIVE
The objective of this study was to develop evidence-based recommendations on pregnancy management for persons with multiple sclerosis (MS).
BACKGROUND
MS typically affects young women in their childbearing years. Increasing evidence is available to inform questions raised by MS patients and health professionals about pregnancy issues.
METHODS
The French Group for Recommendations in Multiple Sclerosis (France4MS) reviewed PubMed and university databases (January 1975 through June 2021). The RAND/UCLA appropriateness method was developed to synthesise the scientific literature and expert opinions on healthcare topics; it was used to reach a formal agreement. Fifty-six MS experts worked on the full-text review and initial wording of recommendations. A group of 62 multidisciplinary healthcare specialists validated the final proposal of summarised evidence.
RESULTS
A strong agreement was reached for all 104 proposed recommendations. They cover diverse topics, such as pregnancy planning, follow-up during pregnancy and postpartum, delivery routes, locoregional analgesia or anaesthesia, prevention of postpartum relapses, breastfeeding, vaccinations, reproductive assistance, management of relapses and disease-modifying treatments.
CONCLUSION
The 2022 recommendations of the French MS society should be helpful to harmonise counselling and treatment practice for pregnancy in persons with MS, allowing for better and individualised choices.

Identifiants

pubmed: 36317497
doi: 10.1177/13524585221129472
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

11-36

Auteurs

Sandra Vukusic (S)

Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Service de Neurologie, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France/INSERM 1028 et CNRS UMR 5292, Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, Bron, France/Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France/Eugène Devic EDMUS Foundation against Multiple Sclerosis, State-approved Foundation, Bron, France.

Clarisse Carra-Dalliere (C)

Neurology Department, Hôpital Gui de Chauliac, CHU de Montpellier, Montpellier, France.

Jonathan Ciron (J)

Centre Ressources et Compétences sclérose en plaques (CRC-SEP) et Service de Neurologie B4, Hôpital Pierre-Paul Riquet, CHU Toulouse Purpan, Toulouse, France INSERM UMR1291 - CNRS UMR5051, Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse 3, Toulouse, France.

Elisabeth Maillart (E)

Neurology Department, Pitié-Salpêtrière Hospital, CRC-SEP, Paris, France.

Laure Michel (L)

Neurology Department, CIC_P1414 INSERM, Rennes University Hospital, Rennes, France.

Emmanuelle Leray (E)

EHESP, CNRS, Inserm, Arènes - UMR 6051, RSMS (Recherche sur les Services et Management en Santé) - U 1309, Université de Rennes, Rennes, France.

Anne-Marie Guennoc (AM)

CRC SEP et Service de Neurologie, CHU Tours, Tours, France.

Bertrand Bourre (B)

Department of Neurology, CHU Rouen, Rouen, France.

David Laplaud (D)

Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes Université and INSERM, Nantes, France/CIC INSERM 1413, CRC-SEP Pays de la Loire, CHU Nantes, Nantes, France.

Géraldine Androdias (G)

Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Service de Neurologie, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France/Clinique de la Sauvegarde, Ramsay Santé, Lyon, France.

Caroline Bensa (C)

CRC-SEP, Neurology Department, Hôpital Fondation Adolphe de Rothschild, Paris, France.

Kevin Bigaut (K)

CRC-SEP, Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Damien Biotti (D)

Centre Ressources et Compétences sclérose en plaques (CRC-SEP) et Service de Neurologie B4, Hôpital Pierre-Paul Riquet, CHU Toulouse Purpan, Toulouse, France INSERM UMR1291 - CNRS UMR5051, Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse 3, Toulouse, France.

Pierre Branger (P)

Service de Neurologie, CHU de Caen Normandie, Caen, France.

Olivier Casez (O)

Pathologies Inflammatoires du Système Nerveux, Neurologie, CHU Grenoble Alpes, Grenoble, France/Translational Research in Autoimmunity and Inflammation Group (T-RAIG), TIMC-IMAG, Université de Grenoble Alpes, Grenoble, France.

Mikael Cohen (M)

CRCSEP Côte d'Azur, CHU de Nice Pasteur 2, Nice, France/Université Nice Côte d'Azur UR2CA-URRIS, Nice, France.

Elodie Daval (E)

Service de Neurologie, CHU de Besançon, Besançon, France.

Romain Deschamps (R)

CRC-SEP, Neurology Department, Hôpital Fondation Adolphe de Rothschild, Paris, France.

Cécile Donze (C)

Hôpital saint Philibert, Groupement des Hôpitaux de l'Institut Catholique de Lille, Faculté de médecine et de maïeutique de Lille, Lomme, France.

Anne-Laure Dubessy (AL)

Department of Neurology, Saint-Antoine Hospital, APHP-6, Paris, France/Sorbonne University, Paris, France.

Cécile Dulau (C)

CRC-SEP, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France.

Françoise Durand-Dubief (F)

Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Service de Neurologie, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France.

Maxime Guillaume (M)

Department of Neurology, CHU Rouen, Rouen, France.

Benjamin Hebant (B)

Department of Neurology, CHU Rouen, Rouen, France.

Laurent Kremer (L)

CRC-SEP, Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Arnaud Kwiatkowski (A)

Department of Neurology, Lille Catholic Hospitals, Lille Catholic University, Lille, France.

Julien Lannoy (J)

Service de Neurologie, Centre Hospitalier de Lens, Lens, France.

Adil Maarouf (A)

CRMBM, UMR 7339, CNRS, Aix-Marseille Université, Marseille, France/APHM Hôpital de la Timone, Marseille, France.

Eric Manchon (E)

Department of Neurology, Gonesse Hospital, Gonesse, France.

Guillaume Mathey (G)

Service de neurologie, Centre Hospitalier Régional Universitaire de Nancy - Hôpital Central, Nancy, France.

Xavier Moisset (X)

Neuro-Dol, Inserm, Université Clermont Auvergne, Clermont-Ferrand, France/Department of neurology et CRC-SEP, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Alexis Montcuquet (A)

CRC-SEP, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France.

Julie Pique (J)

Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Service de Neurologie, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France/INSERM 1028 et CNRS UMR 5292, Centre de Recherche en Neurosciences de Lyon, Bron, France/Université Claude Bernard Lyon 1, Lyon, France.

Thomas Roux (T)

Neurology Department, Pitié-Salpêtrière Hospital, CRC-SEP, Paris, France.

Romain Marignier (R)

Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Service de Neurologie, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France/INSERM 1028 et CNRS UMR 5292, Centre de Recherche en Neurosciences de Lyon, Lyon, France/Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.

Christine Lebrun-Frenay (C)

Service de Neurologie, CHU de Besançon, Besançon, France/Université Nice Côte d'Azur UR2CA-URRIS, Nice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH